Samitivej Hospital welcomes Takeda Co. Ltd., in pursuing the building of immunity through vaccines and moving towards becoming the medical hub of Southeast Asia

Surangkana Techapaitoon, M.D., Deputy CEO of Samitivej and BNH Hospitals, and Director of Samitivej Children’s Hospital, and a team of executives were on hand to welcome Gamze Yüceland, President of the Growth and Emerging Markets Business Unit at Takeda Co. Ltd., and a team of Takeda executives. Discussions were held on the importance of disease prevention through vaccination, advocating for Dengue fever prevention in Thailand, and moving towards becoming the medical hub of Southeast Asia. During the meeting, the Takeda team received a new type of Dengue fever vaccine available at Samitivej Hospital. This vaccine is suitable for individuals aged 4-60 years and has proven to be 80.2% effective in preventing all serotypes of Dengue fever, with a 90.4% reduction in the need for hospitalization. The vaccine can be administered whether or not an individual has previously had Dengue fever, without the need for prior immunity testing. It is important to note that the vaccine is safe. Samitivej Hospital is actively advocating for a Dengue fever-free Thailand through vaccination. We aim to prevent dengue fever with vaccination because we don't want anyone to get sick.

Read the full article about the Dengue fever vaccine here: https://smtvj.com/Dengue-EN